July 7, 1993

Outcome After Allogeneic Bone Marrow Transplant for Leukemia in Older Adults

Author Affiliations

From Huddinge Hospital, Huddinge, Sweden (Dr Ringdén); the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee (Drs Horowitz, Rimm, and Bortin and Ms Veum-Stone); UCLA Center for Health Sciences, Los Angeles, Calif (Drs Gale and Gajewski); St Vincent's Hospital, Darlinghurst, Australia (Dr Biggs); Kantonsspital, Basel, Switzerland (Dr Speck); and University of Nijmegen, the Netherlands (Dr de Witte).

JAMA. 1993;270(1):57-60. doi:10.1001/jama.1993.03510010063030

Objective.  —To determine whether age over 40 years is associated with adverse outcome after allogeneic bone marrow transplantation for leukemia.

Design.  —A retrospective analysis of outcome after bone marrow transplants for leukemia reported to the International Bone Marrow Transplant Registry (IBMTR) among recipients 30 through 39 years, 40 through 44 years, 45 through 49 years, and 50 years of age and older.

Setting.  —Transplantations performed in 138 institutions worldwide and reported to the IBMTR.

Patients.  —A total of 2180 recipients of HLA-identical sibling bone marrow transplants for leukemia, divided into four cohorts based on age: 30 through 39 years (n=1282), 40 through 44 years (n=527), 45 through 49 years (n=291), and 50 years and older (n=80).

Main Outcome Measures and Results.  —Incidence of leukemia-free survival, graft-vs-host disease, and relapse was comparable among the four age cohorts. Patients with advanced leukemia aged 45 years or older had a slightly higher risk of treatment-related mortality, and the 45- through 49-year-old cohort had a higher risk of interstitial pneumonia.

Conclusions.  —These data indicate that among leukemia patients over 30 years of age at the time of allogeneic bone marrow transplantation, increasing age into the fifth decade does not adversely affect outcome after transplants from HLA-identical siblings.(JAMA. 1993;270:57-60)